Antitumor activity of a novel antisense oligonucleotide against Akt1

Heejeong Yoon, Joong Kim Deog, Hyun Ahn Eun, Ginelle C. Gellert, Jerry W. Shay, Chang Ho Ahn, Bok Lee Young

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The AKT pathway is an important therapeutic target for cancer drug discovery as it functions as a main point for transducing extracellular and intracellular oncogenic signals. Moreover, alternations of the AKT pathway have been found in a wide range of cancers. In the present study, we found that an Akt1 antisense oligonucleotide (Akt1 AO) significantly downregulated the expression of AKT1 at both the mRNA and protein levels and inhibited cellular growth at nanomolar concentrations in various types of human cancer cells. Combined treatment of Akt1 AO with several cytotoxic drugs resulted in an additive growth inhibition of Caki-1 cells. The in vivo effectiveness of Akt1 AO was determined using two different xenograft nude mouse models. Akt1 AO (30 mg/kg, i.v. every 48 h) significantly inhibited the tumor growth of nude mouse subcutaneously implanted with U251 human glioblastoma cells after 27 days treatment. Akt1 AO (30 mg/kg, i.p continuously via osmotic pump) also significantly inhibited the tumor formation in nude mice implanted with luciferase-expressing MIA human pancreatic cancer cells (MIA-Luc) after 14 days of treatment. The luciferase signals from MIA-Luc cells were reduced or completely abolished after 2 weeks of treatment and the implanted tumors were barely detectable. Our findings suggest that Akt1 AO alone or in combination with other clinically approved anticancer agents should be further explored and progressed into clinical studies as a potential novel therapeutic agent.

Original languageEnglish (US)
Pages (from-to)832-838
Number of pages7
JournalJournal of Cellular Biochemistry
Volume108
Issue number4
DOIs
StatePublished - Nov 1 2009

Fingerprint

Antisense Oligonucleotides
Nude Mice
Tumors
Neoplasms
Luciferases
Growth
Cells
Drug Discovery
Glioblastoma
Pancreatic Neoplasms
Heterografts
Antineoplastic Agents
Down-Regulation
Pumps
Messenger RNA
Therapeutics
Pharmaceutical Preparations
Proteins

Keywords

  • AKT1 AO
  • Anticancer
  • Antisense oligonucleotide
  • Combination

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Yoon, H., Deog, J. K., Eun, H. A., Gellert, G. C., Shay, J. W., Ahn, C. H., & Young, B. L. (2009). Antitumor activity of a novel antisense oligonucleotide against Akt1. Journal of Cellular Biochemistry, 108(4), 832-838. https://doi.org/10.1002/jcb.22311

Antitumor activity of a novel antisense oligonucleotide against Akt1. / Yoon, Heejeong; Deog, Joong Kim; Eun, Hyun Ahn; Gellert, Ginelle C.; Shay, Jerry W.; Ahn, Chang Ho; Young, Bok Lee.

In: Journal of Cellular Biochemistry, Vol. 108, No. 4, 01.11.2009, p. 832-838.

Research output: Contribution to journalArticle

Yoon, H, Deog, JK, Eun, HA, Gellert, GC, Shay, JW, Ahn, CH & Young, BL 2009, 'Antitumor activity of a novel antisense oligonucleotide against Akt1', Journal of Cellular Biochemistry, vol. 108, no. 4, pp. 832-838. https://doi.org/10.1002/jcb.22311
Yoon, Heejeong ; Deog, Joong Kim ; Eun, Hyun Ahn ; Gellert, Ginelle C. ; Shay, Jerry W. ; Ahn, Chang Ho ; Young, Bok Lee. / Antitumor activity of a novel antisense oligonucleotide against Akt1. In: Journal of Cellular Biochemistry. 2009 ; Vol. 108, No. 4. pp. 832-838.
@article{28e87830f1404234a67808749cdcb9dc,
title = "Antitumor activity of a novel antisense oligonucleotide against Akt1",
abstract = "The AKT pathway is an important therapeutic target for cancer drug discovery as it functions as a main point for transducing extracellular and intracellular oncogenic signals. Moreover, alternations of the AKT pathway have been found in a wide range of cancers. In the present study, we found that an Akt1 antisense oligonucleotide (Akt1 AO) significantly downregulated the expression of AKT1 at both the mRNA and protein levels and inhibited cellular growth at nanomolar concentrations in various types of human cancer cells. Combined treatment of Akt1 AO with several cytotoxic drugs resulted in an additive growth inhibition of Caki-1 cells. The in vivo effectiveness of Akt1 AO was determined using two different xenograft nude mouse models. Akt1 AO (30 mg/kg, i.v. every 48 h) significantly inhibited the tumor growth of nude mouse subcutaneously implanted with U251 human glioblastoma cells after 27 days treatment. Akt1 AO (30 mg/kg, i.p continuously via osmotic pump) also significantly inhibited the tumor formation in nude mice implanted with luciferase-expressing MIA human pancreatic cancer cells (MIA-Luc) after 14 days of treatment. The luciferase signals from MIA-Luc cells were reduced or completely abolished after 2 weeks of treatment and the implanted tumors were barely detectable. Our findings suggest that Akt1 AO alone or in combination with other clinically approved anticancer agents should be further explored and progressed into clinical studies as a potential novel therapeutic agent.",
keywords = "AKT1 AO, Anticancer, Antisense oligonucleotide, Combination",
author = "Heejeong Yoon and Deog, {Joong Kim} and Eun, {Hyun Ahn} and Gellert, {Ginelle C.} and Shay, {Jerry W.} and Ahn, {Chang Ho} and Young, {Bok Lee}",
year = "2009",
month = "11",
day = "1",
doi = "10.1002/jcb.22311",
language = "English (US)",
volume = "108",
pages = "832--838",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Antitumor activity of a novel antisense oligonucleotide against Akt1

AU - Yoon, Heejeong

AU - Deog, Joong Kim

AU - Eun, Hyun Ahn

AU - Gellert, Ginelle C.

AU - Shay, Jerry W.

AU - Ahn, Chang Ho

AU - Young, Bok Lee

PY - 2009/11/1

Y1 - 2009/11/1

N2 - The AKT pathway is an important therapeutic target for cancer drug discovery as it functions as a main point for transducing extracellular and intracellular oncogenic signals. Moreover, alternations of the AKT pathway have been found in a wide range of cancers. In the present study, we found that an Akt1 antisense oligonucleotide (Akt1 AO) significantly downregulated the expression of AKT1 at both the mRNA and protein levels and inhibited cellular growth at nanomolar concentrations in various types of human cancer cells. Combined treatment of Akt1 AO with several cytotoxic drugs resulted in an additive growth inhibition of Caki-1 cells. The in vivo effectiveness of Akt1 AO was determined using two different xenograft nude mouse models. Akt1 AO (30 mg/kg, i.v. every 48 h) significantly inhibited the tumor growth of nude mouse subcutaneously implanted with U251 human glioblastoma cells after 27 days treatment. Akt1 AO (30 mg/kg, i.p continuously via osmotic pump) also significantly inhibited the tumor formation in nude mice implanted with luciferase-expressing MIA human pancreatic cancer cells (MIA-Luc) after 14 days of treatment. The luciferase signals from MIA-Luc cells were reduced or completely abolished after 2 weeks of treatment and the implanted tumors were barely detectable. Our findings suggest that Akt1 AO alone or in combination with other clinically approved anticancer agents should be further explored and progressed into clinical studies as a potential novel therapeutic agent.

AB - The AKT pathway is an important therapeutic target for cancer drug discovery as it functions as a main point for transducing extracellular and intracellular oncogenic signals. Moreover, alternations of the AKT pathway have been found in a wide range of cancers. In the present study, we found that an Akt1 antisense oligonucleotide (Akt1 AO) significantly downregulated the expression of AKT1 at both the mRNA and protein levels and inhibited cellular growth at nanomolar concentrations in various types of human cancer cells. Combined treatment of Akt1 AO with several cytotoxic drugs resulted in an additive growth inhibition of Caki-1 cells. The in vivo effectiveness of Akt1 AO was determined using two different xenograft nude mouse models. Akt1 AO (30 mg/kg, i.v. every 48 h) significantly inhibited the tumor growth of nude mouse subcutaneously implanted with U251 human glioblastoma cells after 27 days treatment. Akt1 AO (30 mg/kg, i.p continuously via osmotic pump) also significantly inhibited the tumor formation in nude mice implanted with luciferase-expressing MIA human pancreatic cancer cells (MIA-Luc) after 14 days of treatment. The luciferase signals from MIA-Luc cells were reduced or completely abolished after 2 weeks of treatment and the implanted tumors were barely detectable. Our findings suggest that Akt1 AO alone or in combination with other clinically approved anticancer agents should be further explored and progressed into clinical studies as a potential novel therapeutic agent.

KW - AKT1 AO

KW - Anticancer

KW - Antisense oligonucleotide

KW - Combination

UR - http://www.scopus.com/inward/record.url?scp=70350435062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350435062&partnerID=8YFLogxK

U2 - 10.1002/jcb.22311

DO - 10.1002/jcb.22311

M3 - Article

C2 - 19693774

AN - SCOPUS:70350435062

VL - 108

SP - 832

EP - 838

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 4

ER -